Company Filing History:

17 out of 6,662

Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Years Active: 1989-2002

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6395689 - Terpene ethers and their use (2002-05-28),

2. 6211196 - Benzyloxy-substituted, fused N-heterocycles, processes for their preparation, and their use as bradykinin receptor antagonists (2001-04-03),

3. 6140341 - Aminoalkyl and acylaminoalkyl ethers, process for their preparation, and (2000-10-31),

4. 5859025 - Fluoroalkyl- and fluoroalkoxy-substituted heterocyclic bradykinin (1999-01-12),

5. 5834500 - Sulfur-containing heterocyclic bradykinin antagonists, process for their (1998-11-10),

6. 5786365 - Use of nonpeptide bradykinin antagonists for the treatment and (1998-07-28),

7. 5750728 - Process for the preparation of aromatic bromomethyl compounds (1998-05-12),

8. 5635525 - Benzimidazole derivatives as angiotensin II receptor antagonists, (1997-06-03),

9. 5633400 - Process for the preparation of biphenyl derivatives (1997-05-27),

10. 5618975 - Process for the preparation of biphenyl derivatives (1997-04-08),

11. 5612365 - Angiotensin II receptor antagonists for the treatment and prophylaxis of (1997-03-18),

12. 5604251 - Imidazole derivatives with a biphenylsulfonylurea or (1997-02-18),

13. 5527919 - Process for the preparation of (1996-06-18),

14. 5482957 - Azole derivatives, process for their preparation and their use (1996-01-09),

15. 5475004 - Angiotensin II receptor antagonists for the treatment and prophylaxis of (1995-12-12),

Title: Adalbert Wagner: Innovator in Medicinal Chemistry

Introduction: Adalbert Wagner, based in Hattersheim am Main, Germany, is a prolific inventor with a remarkable portfolio of 21 patents. His work primarily focuses on the development of novel therapeutic compounds, particularly in the realm of medicinal chemistry.

Latest Patents: Among his recent innovations, Wagner has developed patents related to terpene ethers and their applications. Notably, he has worked on benzyloxy-substituted, fused N-heterocycles, which have shown potential as bradykinin receptor antagonists. These compounds may play a significant role in the treatment and prevention of serious conditions such as liver cirrhosis and Alzheimer's disease. The patent details processes for the preparation and use of these compounds, which include various derivatives of formula (I).

Career Highlights: Wagner has had a dynamic career with key roles in influential companies, including Hoechst Aktiengesellschaft and Clariant Corporation. His contributions in these organizations have been instrumental in advancing chemical research and patent development, allowing him to leverage his expertise in the field of medicinal chemistry.

Collaborations: Throughout his career, Adalbert Wagner has collaborated with esteemed coworkers, including Holger Heitsch and Bernward Scholkens. These partnerships have facilitated innovative research and the successful development of new pharmaceutical compounds.

Conclusion: Adalbert Wagner's contributions to the field of medicinal chemistry are noteworthy, with his extensive patent portfolio reflecting a commitment to innovation. His work has the potential to impact the treatment landscape for various diseases, positioning him as a significant figure in pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com